J&J(US:JNJ) Xin Lang Cai Jing·2026-01-09 05:01Core Viewpoint - Johnson & Johnson has reached an agreement with the Trump administration to lower drug prices for Americans in exchange for tariff exemptions on its pharmaceutical products [1][3]. Group 1: Drug Pricing Agreement - The agreement aims to align U.S. drug prices with those in other wealthy countries, as American patients currently pay nearly three times more for prescription drugs compared to other developed nations [1][3]. - Specific terms of the agreement, including details on revised drug prices and which drugs are covered, have not been disclosed [1][3]. - Johnson & Johnson will participate in the TrumpRx.gov website, allowing Americans to purchase its drugs at significantly discounted prices [1][3]. Group 2: Medicaid and Investment Plans - The agreement is part of a broader initiative where nine major U.S. pharmaceutical companies agreed to lower prices for drugs sold to low-income individuals under the Medicaid program, promising substantial savings on commonly used medications [1][3]. - As part of a previously announced $55 billion investment plan, Johnson & Johnson will establish two new manufacturing facilities in North Carolina and Pennsylvania [4]. - The company indicated that it may announce additional U.S. investment plans later this year [5].